Rising expenses without a corresponding rise in revenue can indicate operational bloat or aggressive expansion efforts.
The sum of all costs required to run the business that are not directly tied to production, including R&D and SG&A. It r...
Investors compare this to revenue to assess the 'operating leverage' of a business model.
total_operating_expenses| Segment | Q1 '26 |
|---|---|
| Pharmaceutical and Specialty Solutions | $55.33B |
| Cost of product sold | $3.12B |
| Other Segments | $1.53B |
| Total | — |